Trial reportBMC gastroenterology2025
Prehabilitation for patients undergoing endoscopic submucosal dissection: a randomized controlled trial.
Trial report in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopic submucosal dissection (ESD) is a minimally invasive therapy for early gastrointestinal neoplasms, but patients may experience reduced functional capacity and delayed recovery post-procedure. Prehabilitation, has shown benefits in major surgery by improving physical fitness and recovery. We hypothesized that a structured prehabilitation regimen before ESD would enhance postoperative functional recovery and patient outcomes compared to standard care.
methodsSingle-center, assessor-blinded randomized controlled trial of 100 adults undergoing elective ESD, randomized to 4-week prehabilitation (supervised aerobic/resistance training 3×/week, individualized nutrition with protein supplementation, and psychological support) or usual care (standard instructions without structured exercise or nutrition). The primary outcome was change in six-minute walk distance (6MWD) from baseline to 1 month. Secondary outcomes included handgrip strength, quality of life (SF-36), psychological health (HADS), postoperative complications, length of stay, and 90-day readmissions.
resultsBaseline characteristics were similar between groups. At 1-month post-ESD, six-minute walk distance had decreased in both groups with no significant between-group difference (mean change from baseline - 40.9 m in prehabilitation vs. - 53.3 m in controls, p = 0.439). By 3 months, the prehabilitation group surpassed their baseline walking distance (18.9 m), whereas controls remained below baseline (- 14.1 m), indicating superior functional recovery with prehabilitation (p = 0.022). Prehabilitation also led to greater improvements in early postoperative strength and patient-reported outcomes. At 1 month, handgrip strength increased more in the prehabilitation group (mean 5.6 kg vs. 4.1 kg, p = 0.001). Anxiety symptoms improved significantly with prehabilitation (HADS anxiety score change - 1.17 vs. - 0.22, p = 0.003), with a parallel significant reduction in depression scores (p = 0.002). Prehabilitation patients reported higher gains in mental quality-of-life by 3 months (SF-36 mental component + 15.4 vs. + 11.4 points, p < 0.001). There were no significant differences in perioperative safety outcomes, average hospital stay, and 90-day readmission rates.
conclusionsA 4-week multimodal prehabilitation program for ESD patients significantly improved postoperative functional capacity and psychological well-being without increasing complication rates or hospital stay. Prehabilitation is a safe and effective strategy to enhance recovery and patient-centered outcomes in ESD. CLINICAL
trial registrationThis trial was retrospectively registered in the Chinese Clinical Trial Registry (ChiCTR) (registration number: ChiCTR2500103062) on May 23, 2025. LEVEL OF EVIDENCE: Level I (Randomized Controlled Trial).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.